• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Pacira BioSciences Inc.

    4/29/25 4:11:36 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCRX alert in real time by email
    DEFA14A 1 tm2428503d4_defa14a.htm DEFA14A

     

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No.    )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material under §240.14a-12

     

    PACIRA BIOSCIENCES, INC.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)​

     

    Payment of Filing Fee (Check all boxes that apply):

     

    x No fee required
       
    ¨ Fee paid previously with preliminary materials
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

    GRAPHIC

    Get informed before you vote *If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number Your Vote Counts! FLASHID-JOB# For complete information and to vote, visit www.ProxyVote.com Control # Ricky Campana P.O. Box 123456 Suite 500 51 Mercedes Way Edgewood, NY 11717 148,294 322,224 1 OF 2 30# Hextone, Inc. P.O. Box 9142 Farmingdale, NY 11735 XXXX XXXX XXXX XXXX PACIRA BIOSCIENCES, INC. 2025 Annual Meeting Vote by June 09, 2025 11:59 PM ET You invested in PACIRA BIOSCIENCES, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 10, 2025. View the Notice & Proxy Statement, Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 27, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote in Person at the Meeting* June 10, 2025 1:30 PM EDT 5 Sylvan Way, Suite 300 Parsippany, NJ 07054 Vote in Person or Virtually at the Meeting: www.cesonlineservices.com/pcrx25_vm

    GRAPHIC

    Voting Items Board Recommends THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com FLASHID-JOB# Control # XXXX XXXX XXXX XXXX 1.00000 322,224 148,294 Under New York Stock Exchange rules, brokers may vote “routine” matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting. We will nevertheless follow your instructions, even if the broker’s discretionary vote has already been given, provided your instructions are received prior to the meeting date. PACIRA BIOSCIENCES, INC. 2025 Annual Meeting Vote by June 09, 2025 11:59 PM ET 1. Election of Directors Nominees: 01 Marcelo Bigal 02 Frank D. Lee 03 Alethia Young For 2 Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3 Approval, on an advisory basis, of the compensation of our named executive officers. For 4 Advisory vote to approve the frequency of future advisory votes to approve the compensation of our named executive officers. Year 5 Approval of our Amended and Restated 2011 Stock Incentive Plan. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

    Get the next $PCRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PCRX

    DatePrice TargetRatingAnalyst
    12/9/2025$27.00Equal Weight
    Barclays
    11/17/2025Buy
    H.C. Wainwright
    7/25/2025$30.00Hold → Buy
    Truist
    1/30/2025$8.00 → $25.00Sell → Hold
    Truist
    8/13/2024$30.00 → $8.00Buy → Sell
    Truist
    8/12/2024$42.00 → $11.00Overweight → Neutral
    Piper Sandler
    8/12/2024$45.00 → $10.00Overweight → Underweight
    JP Morgan
    8/12/2024Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $PCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bigal Marcelo bought $20,034 worth of shares (1,512 units at $13.25), increasing direct ownership by 18% to 10,142 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/19/24 8:25:55 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Brege Laura bought $12,810 worth of shares (1,000 units at $12.81), increasing direct ownership by 6% to 17,552 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/19/24 8:25:46 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Yang Michael J. bought $25,800 worth of shares (2,000 units at $12.90), increasing direct ownership by 38% to 7,230 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/14/24 4:35:09 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pacira to Report 2025 Financial Results on Thursday February 26, 2026

    BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call.

    2/12/26 4:01:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices

    BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction ("NOPAIN") Act. Made up of more than 250 organizations dedicated to preventing opioid addiction before it starts, Voices is the nation's leading nonpartisan coalition dedicated to ensuring patient access to non-addictive pain management approaches Data were gathered from a national awareness, trial, and usage (ATU) survey of nearly 750 hospitals, he

    2/12/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the "Inducement Plan") as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the "Committee") without stockholder approval. Four employees received stock options to purchas

    2/9/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    SEC Filings

    View All

    SEC Form 144 filed by Pacira BioSciences Inc.

    144 - Pacira BioSciences, Inc. (0001396814) (Subject)

    2/2/26 10:55:35 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Pacira BioSciences, Inc. (0001396814) (Filer)

    1/28/26 8:01:57 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Pacira BioSciences, Inc. (0001396814) (Filer)

    1/8/26 4:02:31 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Pacira BioSciences with a new price target

    Barclays initiated coverage of Pacira BioSciences with a rating of Equal Weight and set a new price target of $27.00

    12/9/25 8:52:11 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Pacira BioSciences

    H.C. Wainwright initiated coverage of Pacira BioSciences with a rating of Buy

    11/17/25 9:41:22 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences upgraded by Truist with a new price target

    Truist upgraded Pacira BioSciences from Hold to Buy and set a new price target of $30.00

    7/25/25 8:53:01 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President, Finance Riker Lauren covered exercise/tax liability with 2,751 shares and sold $83,240 worth of shares (4,000 units at $20.81), decreasing direct ownership by 11% to 52,313 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    2/3/26 6:24:09 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Administrative Officer Williams Kristen covered exercise/tax liability with 17,134 shares and sold $269,703 worth of shares (13,137 units at $20.53), decreasing direct ownership by 19% to 131,303 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    2/3/26 6:24:01 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Teehan Brendan covered exercise/tax liability with 5,182 shares, decreasing direct ownership by 10% to 49,220 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    2/3/26 6:23:46 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Leadership Updates

    Live Leadership Updates

    View All

    Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

    -- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the appointment of Samit Hirawat, M.D., to its Board of Directors. This appointment increases the size of the company's Board of Directors to 10 members. "Samit is an accomplished and widely respected leader in the biopharmaceutical industry, and we are pleased to welcome him to our Board of Directors," said Laura Brege, independent board chair of Pacira. "We believ

    1/28/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

    -- LG Chem becomes exclusive distributor of EXPAREL --  – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced it has entered into an agreement with LG Chem designed to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets. Through this partnership, LG Chem has the exclusive rights to commercialize EXPAREL® (bupivacaine liposome injectable suspension), Pacira's long-actin

    1/13/26 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

    --Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries-- BRISBANE, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pacira Biosciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints using Big data Evaluation) Consortium, a pioneering initiative to revolutionize osteoarthritis (OA) research and improve patient care and outcomes on a global scale. "Despite its prevalence, there c

    12/18/25 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    1/19/24 2:40:54 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    2/14/23 1:31:32 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    1/23/23 3:52:35 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Financials

    Live finance-specific insights

    View All

    Pacira to Report 2025 Financial Results on Thursday February 26, 2026

    BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call.

    2/12/26 4:01:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

    -- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Total revenues of $179.5 millionNet product sales of $139.9 million for EXPAREL; $29.0 million for ZILRETTA; and $6.5 million for iovera°Net income of $5.4 million, or $0.12 per sha

    11/6/25 4:01:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

    BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the co

    10/30/25 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care